ChemLifeIntel
Access

Nomax Inc.

HIGH RISKHQ: — · Private · Founded —
LISTINGPrivateFOUNDED0
FOCUS THERAPY AREAS
Manufacturer
COMPANY INTELLIGENCE SNAPSHOTlive
0
Manufacturing Sites
1
Intelligence Briefs
0
Active Regulatory Actions
HQ Country
NO ACTIVE REGULATORY ACTIONSClean compliance footprint across 0 monitored sites · HQ
View regulatory detail

INTELLIGENCE

Showing 1 of 1 briefs on Nomax Inc.
REGULATORY INTELLIGENCE·Recall

FDA Class II Recall: Nomax Inc.'s Fluorescein Sodium Ophthalmic Strips Fail USP Impurity Specifications

Nomax Inc. has initiated a Class II recall (D-0462-2024) for 15,056 cartons of GLOSTRIPS, Fluorescein Sodium Ophthalmic Strips, due to active pharmaceutical ingredient (API) non-compliance with USP monograph specifications for unspecified impurities. This voluntary nationwide recall highlights critical quality control failures in API manufacturing, posing immediate supply chain risks for ophthalmic diagnostic products and underscoring the need for rigorous supplier qualification.

90-Day Activity
NomaxGLOSTRIPS
MKMeera Krishnan· Senior Regulatory Intelligence Analyst
2024-05-01